



# UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE  
United States Patent and Trademark Office  
Address: COMMISSIONER FOR PATENTS  
P.O. Box 1450  
Alexandria, Virginia 22313-1450  
www.uspto.gov

SM

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/062,875	01/31/2002	Franklin R. Cockerill	07039-253001	2265

26191 7590 02/24/2004

FISH & RICHARDSON P.C.  
3300 DAIN RAUSCHER PLAZA  
60 SOUTH SIXTH STREET  
MINNEAPOLIS, MN 55402

EXAMINER

STRZELECKA, TERESA E

ART UNIT	PAPER NUMBER
----------	--------------

1637

DATE MAILED: 02/24/2004

Please find below and/or attached an Office communication concerning this application or proceeding.

**Office Action Summary**

Application No,

10/062,875

Applicant(s)

COCKERILL ET AL.

Examiner

Teresa E Strzelecka

Art Unit

1637

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --

**Period for Reply**

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 3 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
  - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely.
  - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
  - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133).
- Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

**Status**

- 1) ☒ Responsive to communication(s) filed on 04 December 2003.
- 2a) ☐ This action is **FINAL**. 2b) ☒ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

**Disposition of Claims**

- 4) ☒ Claim(s) 1-48 is/are pending in the application.
- 4a) Of the above claim(s) 29-39 is/are withdrawn from consideration.
- 5) ☐ Claim(s) \_\_\_\_\_ is/are allowed.
- 6) ☒ Claim(s) 1-28 and 40-48 is/are rejected.
- 7) ☐ Claim(s) \_\_\_\_\_ is/are objected to.
- 8) ☐ Claim(s) \_\_\_\_\_ are subject to restriction and/or election requirement.

**Application Papers**

- 9) ☒ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on \_\_\_\_\_ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
- Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
- Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

**Priority under 35 U.S.C. § 119**

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some \* c) ☐ None of:
1. ☐ Certified copies of the priority documents have been received.
  2. ☐ Certified copies of the priority documents have been received in Application No. \_\_\_\_\_.
  3. ☒ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

\* See the attached detailed Office action for a list of the certified copies not received.

**Attachment(s)**

- 1) ☒ Notice of References Cited (PTO-892)
- 2) ☐ Notice of Draftsperson's Patent Drawing Review (PTO-948)
- 3) ☒ Information Disclosure Statement(s) (PTO-1449 or PTO/SB/08)  
Paper No(s)/Mail Date 28052002.
- 4) ☐ Interview Summary (PTO-413)  
Paper No(s)/Mail Date. \_\_\_\_\_.
- 5) ☐ Notice of Informal Patent Application (PTO-152)
- 6) ☐ Other: \_\_\_\_\_.

## **DETAILED ACTION**

### ***Election/Restrictions***

1. Applicant's election without traverse of Group I (claims 1-28 and 40-48) in Paper No. 04122003 is acknowledged.
2. Claims 29-39 withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention, there being no allowable generic or linking claim. Election was made **without** traverse in Paper No. 04122004.
3. Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i).

### ***Information Disclosure Statement***

4. The information disclosure statement (IDS) submitted on May 28, 2002 is in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner.

### ***Specification***

5. The disclosure is objected to because it contains an embedded hyperlink and/or other form of browser-executable code. Applicant is required to delete the embedded hyperlink and/or other form of browser-executable code. See MPEP § 608.01.

The hyperlinks are on page 19, line 21 and on page 21, line 24.

Appropriate correction is required.

***Claim Rejections - 35 USC § 112***

6. The following is a quotation of the first paragraph of 35 U.S.C. 112:

The specification shall contain a written description of the invention, and of the manner and process of making and using it, in such full, clear, concise, and exact terms as to enable any person skilled in the art to which it pertains, or with which it is most nearly connected, to make and use the same and shall set forth the best mode contemplated by the inventor of carrying out his invention.

7. Claims 1, 4-22, 25-28 and 40-48 are rejected under 35 U.S.C. 112, first paragraph, as failing to comply with the written description requirement. The claim(s) contains subject matter which was not described in the specification in such a way as to reasonably convey to one skilled in the relevant art that the inventor(s), at the time the application was filed, had possession of the claimed invention.

In analysis of the claims for compliance with the written description requirement of 35 U.S.C. 112, first paragraph, the written description guidelines note regarding genus/species situations that "Satisfactory disclosure of a ``representative number" depends on whether one of skill in the art would recognize that the applicant was in possession of the necessary common attributes or features of the elements possessed by the members of the genus in view of the species disclosed." (See: Federal Register: December 21, 1999 (Volume 64, Number 244), revised guidelines for written description.)

All of the current claims encompass a genus of nucleic acids which are different from those disclosed in the specification. The genus includes variants for which no written description is provided in the specification. Only the particularly named SEQ ID NOs 1-8 represent this large genus in the specification. Thus, applicant has express possession of only four particular IS481 oligonucleotides and four IS1001 oligonucleotides, in a genus which comprises hundreds of millions of different possibilities. Here, no common element or attributes of the sequences are disclosed, not even the presence of certain domains. No structural limitations or requirements

Art Unit: 1637

which provide guidance on the identification of sequences which meet these functional limitations is provided.

It is noted in the recently decided case The Regents of the University of California v. Eli Lilly and Co. 43 USPQ2d 1398 (Fed. Cir. 1997) decision by the CAFC that

"A definition by function, as we have previously indicated, does not suffice to define the genus because it is only an indication of what the gene does, rather than what it is. See *Fiers*, 984 F.2d at 1169- 71, 25 USPQ2d at 1605- 06 (discussing *Amgen*). It is only a definition of a useful result rather than a definition of what achieves that result. Many such genes may achieve that result. The description requirement of the patent statute requires a description of an invention, not an indication of a result that one might achieve if one made that invention. See *In re Wilder*, 736 F.2d 1516, 1521, 222 USPQ 369, 372- 73 (Fed. Cir. 1984) (affirming rejection because the specification does "little more than outlin[e] goals appellants hope the claimed invention achieves and the problems the invention will hopefully ameliorate."). Accordingly, naming a type of material generally known to exist, in the absence of knowledge as to what that material consists of, is not a description of that material. "

In the current situation, the definition of the IS481 or IS1001 primers/probes lack any specific structure, is precisely the situation of naming a type of material which is generally known to likely exist, but, except for the two specific deletions, is in the absence of knowledge of the material composition and fails to provide descriptive support for the generic claim to "a pair of IS481 primers", for example.

It is noted that in *Fiers v. Sugano* (25 USPQ2d, 1601), the Fed. Cir. concluded that

"...if inventor is unable to envision detailed chemical structure of DNA sequence coding for specific protein, as well as method of obtaining it, then conception is not achieved until reduction to practice has occurred, that is, until after gene has been isolated...conception of any chemical substance, requires definition of that substance other than by its functional utility."

The current situation is a definition of the compound solely but its functional utility, as a primer or a probe, without any definition of the particular deletions claimed.

In the instant application, certain specific SEQ ID NOs are described. Also, in Vas-Cath Inc. v. Mahurkar (19 USPQ2d 1111, CAFC 1991), it was concluded that:

"...applicant must also convey, with reasonable clarity to those skilled in art, that applicant, as of filing date sought, was in possession of invention, with invention being, for purposes of "written description" inquiry, whatever is presently claimed."

In the application at the time of filing, there is no record or description which would demonstrate conception of any nucleic acids other than those expressly disclosed which comprise oligonucleotides with SEQ ID NO: 1-8. Therefore, the claims fail to meet the written description requirement by encompassing sequences which are not described in the specification.

8. Claims 8 and 20 are rejected under 35 U.S.C. 112, second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which applicant regards as the invention.

A) Claim 8 is indefinite over the recitation of "... measuring the wavelength emitted by said acceptor fluorescent moiety". What is measured in FRET is the intensity of the light emitted by the acceptor at a certain wavelength, not the wavelength itself.

B) Claim 20 recites the limitation "said control sample comprises said portion of said portion of said IS481 nucleic acid molecule" in lines 1-2. There is insufficient antecedent basis for this limitation in the claim.

Neither claim 1 nor claim 19, from which claim 20 depends, contain a limitation "portion of IS481 nucleic acid molecule".

#### ***Claim Rejections - 35 USC § 102***

9. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action:

A person shall be entitled to a patent unless --

Art Unit: 1637

(b) the invention was patented or described in a printed publication in this or a foreign country or in public use or on sale in this country, more than one year prior to the date of application for patent in the United States.

10. Claims 46 and 47 are rejected under 35 U.S.C. 102(b) as being anticipated by Van der Zee et al. (J. Clin. Microbiol., vol. 31, pp. 2134-2140, 1993 ; cited in the IDS).

Regarding claim 46, Van der Zee et al. teach a method for detecting the presence or absence of *B. pertussis* in a biological sample from an individual, said method comprising:

performing at least one cycling step, wherein a cycling step comprises an amplifying step and a dye-binding step, wherein said amplifying step comprises contacting said sample with a pair of IS481 primers to produce an IS481 amplification product if a *B. pertussis* IS481 nucleic acid molecule is present in said sample, wherein said dye-binding step comprises contacting said IS481 amplification product with a nucleic acid binding dye (Van der Zee et al. teach amplification of *B. pertussis* in samples from patients to detect the presence or absence of *B. pertussis* (Abstract). The samples were amplified with a pair of IS481-specific primers by PCR (page 2135, second paragraph; page 2136, second paragraph). The amplification products were contacted with ethidium bromide (= dye) by electrophoresing them on a gel containing the dye (page 2136, fifth paragraph).); and

detecting the presence or absence of binding of said nucleic acid binding dye to said amplification product (Van der Zee et al. teach detection of the amplification products (Fig. 3 and 4).),

wherein the presence of binding is indicative of the presence of *B. pertussis* in said sample, and wherein the absence of binding is indicative of the absence of *B. pertussis* in said sample (Van der Zee et al. teach that the presence of a 288 bp amplification product indicates presence of *B. pertussis* in the sample; Fig. 3, 4; Table 3; page 2138, last paragraph; page 2139, first paragraph).).

Regarding claim 47, Van der Zee et al. teach ethidium bromide (page 2136, fifth paragraph).

***Claim Rejections - 35 USC § 103***

11. The following is a quotation of 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action:

(a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102 of this title, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made.

12. Claims 1, 4-14, 18-20, 22, 25-28, 40-43 and 48 are rejected under 35 U.S.C. 103(a) as being unpatentable over Van der Zee et al. (J. Clin. Microbiol., vol. 31, pp. 2134-2140, 1993 ; cited in the IDS) and Wittwer et al. (U.S. Patent No. 6,174,670).

A) Claims 1 and 40 will be considered together in the rejection. Claim 1 is drawn to detection of *B. pertussis* using a pair of IS481 primers and two IS481 probes, claim 40 is drawn to detection of *B. pertussis* using a pair of IS481 primers and one IS481 probe.

Regarding claims 1 and 40, Van der Zee et al. teach a method for detecting the presence or absence of *Bordetella pertussis* in a biological sample from an individual, said method comprising:

performing at least one cycling step, wherein a cycling step comprises an amplifying step and a hybridizing step, wherein said amplifying step comprises contacting said sample with a pair of IS481 primers to produce an IS481 amplification product if a *B. pertussis* IS481 nucleic acid molecule is present in said sample, wherein said hybridizing step comprises contacting said sample with a pair of IS481 probes, wherein the members of said pair of IS481 probes hybridize within no more than five nucleotides of each other, wherein a first IS481 probe of said pair of IS481 probes is labeled with a donor fluorescent moiety and a second IS481 probe of said pair of IS481 probes is labeled with a corresponding acceptor fluorescent moiety (Van der Zee et al. teach amplification of *B. pertussis* in samples from patients to detect the presence or absence of *B. pertussis* (Abstract).

The samples were amplified with a pair of IS481-specific primers by PCR (page 2135, second



Art Unit: 1637

paragraph; page 2136, second paragraph). Amplification products are detected with a digoxigenin-labeled probe specific for IS481 sequences (page 2136, fourth and fifth paragraphs.); and

detecting the presence or absence of fluorescence resonance energy transfer (FRET) between said donor fluorescent moiety of said first IS481 probe and said corresponding acceptor fluorescent moiety of said second IS481 probe (Van der Zee et al. teach detection of the amplification products with the labeled probe (Fig. 5).).

Regarding claim 18, Van der Zee et al. teach biological sample in a form of nasopharyngeal swab (page 2135, last paragraph).

Regarding claim 19, Van der Zee et al. teach using a control sample in the amplification reaction (page 2136, third paragraph; Fig. 4; page 2138, second and third paragraphs).

Regarding claim 20, Van der Zee et al. teach the control sample having a portion of the IS481 sequence, since it contains a fragment of E. coli DNA amplified with BP1 (IS481-specific) primer (page 2136, third paragraph; page 2138, second and third paragraphs).

Regarding claim 22, Van der Zee et al. teach a method for detecting the presence or absence of Bordetella parapertussis in a biological sample from an individual, said method comprising:

performing at least one cycling step, wherein a cycling step comprises an amplifying step and a hybridizing step, wherein said amplifying step comprises contacting said sample with a pair of IS1001 primers to produce an IS1001 amplification product if a B. parapertussis IS1001 nucleic acid molecule is present in said sample, wherein said hybridizing step comprises contacting said sample with a pair of IS1001 probes, wherein the members of said pair of IS1001 probes hybridize within no more than five nucleotides of each other, wherein a first IS1001 probe of said pair of IS1001 probes is labeled with a donor fluorescent moiety and a second IS1001 probe of said pair of IS1001 probes is labeled with a corresponding acceptor fluorescent moiety (Van der Zee et al. teach

Art Unit: 1637

amplification of *B. parapertussis* in samples from patients to detect the presence or absence of *B. parapertussis* (Abstract). The samples were amplified with a pair of IS1001-specific primers by PCR (page 2135, second paragraph; page 2136, second paragraph). Amplification products are detected with a digoxigenin-labeled probe specific for IS1001 sequences (page 2136, fourth and fifth paragraphs.); and

detecting the presence or absence of fluorescence resonance energy transfer (FRET) between said donor fluorescent moiety of said first IS1001 probe and said corresponding acceptor fluorescent moiety of said second IS1001 probe (Van der Zee et al. teach detection of the amplification products with ethidium bromide (Fig. 3, 4) and teach detection of amplification products with the probes (Fig. 5).).

Regarding claim 25, Van der Zee et al. teach a method for detecting the presence or absence of *Bordetella pertussis* and/or *Bordetella parapertussis* in a biological sample from an individual, said method comprising:

performing at least one cycling step, wherein a cycling step comprises an amplifying step and a hybridizing step, wherein said amplifying step comprises contacting said sample with a pair of IS481 primers and a pair of IS1001 primers to produce an IS481 amplification product if a *B. pertussis* IS481 nucleic acid molecule is present in said sample and an IS1001 amplification product if a *B. parapertussis* IS1001 nucleic acid molecule is present in said sample, wherein said hybridizing step comprises contacting said sample with a pair of IS481 probes and a pair of IS1001 probes, wherein the members of said pair of IS481 probes hybridize within no more than five nucleotides of each other and wherein the members of said pair of IS1001 probes hybridize within no more than five nucleotides of each other, wherein a first IS481 probe of said pair of IS481 probes is labeled with a donor fluorescent moiety and a second IS481 probe of said pair of IS481 probes is

Art Unit: 1637

labeled with a corresponding acceptor fluorescent moiety, wherein a first IS1001 probe of said pair of IS1001 probes is labeled with a donor fluorescent moiety and a second IS1001 probe of said pair of IS1001 probes is labeled with a corresponding acceptor fluorescent moiety (Van der Zee et al. teach simultaneous amplification of *B. pertussis* and *B. parapertussis* in samples from patients to detect the presence or absence of *B. pertussis* and/or *B. parapertussis* (Abstract). The samples were amplified with a pair of IS481-specific primers and pair of IS1001-specific primers by PCR (page 2135, second paragraph; page 2136, second paragraph). Amplification products are detected with a digoxigenin-labeled probe specific for IS481 or IS1001 sequences (page 2136, fourth and fifth paragraphs; Fig. 5).); and

detecting the presence or absence of fluorescence resonance energy transfer (FRET) between said donor fluorescent moiety of said first IS1001 probe and said corresponding acceptor fluorescent moiety of said second IS1001 probe (Van der Zee et al. teach detection of the amplification products with ethidium bromide (Fig. 3, 4) and teach detection of amplification products with the probes (Fig. 5).).

B) Van der Zee et al. do not teach detection of amplification products with a probe consisting of two segments, one of which is labeled with donor and the other with acceptor, or limitations of claims 4-14, 26-28, 41, 42 or 48.

C) Wittwer et al. teach real-time detection of amplification products.

Regarding claims 1, 22 and 25, Wittwer et al. teach detection of amplification products in real time by using two probes, one labeled with a fluorescent donor, the other with a fluorescent acceptor (col. 5, lines 21-41; Fig. 5C). The probe detection utilizes the fluorescence resonance energy transfer (FRET) (col. 19, lines 40-63). The fluorescence is monitored for both of the fluorophores (col. 21, lines 58-65). The probes were used to monitor amplification of different

Art Unit: 1637

starting amounts of beta-globin. The presence of FRET between the two fluorophores was indicative of the presence of nucleic acid template in the sample (col. 30, lines 30-60, col. 31, lines 22-28; Fig. 17). The optimum spacing of the probes is from zero to 5 bases (col. 28, lines 8-26).

Regarding claims 4, 5 and 42, Wittwer et al. teach that the optimum spacing of the probes is from zero to 5 bases, with the highest signal occurring with one base between the probes (col. 28, lines 8-26; Fig. 12).

Regarding claim 6, Wittwer et al. teach the donor moiety being fluorescein (col. 25, lines 62-65; col. 28, lines 8-26).

Regarding claim 7, Wittwer et al. teach the acceptor moiety being Cy5 or Cy5.5 (col. 26, lines 5-26, 28-67; col. 27, lines 1-10, 20-27; col. 28, lines 8-26).

Regarding claim 8, Wittwer et al. teach detection by exciting the sample at a wavelength absorbed by the donor and measuring the intensity of the fluorescence emitted by the acceptor (col. 21, lines 60-65; Fig. 8; col. 27, lines 5-10; Fig. 9).

Regarding claim 9, Wittwer et al. teach quantitation of FRET (col. 21, lines 60-65; Fig. 8; col. 27, lines 5-10; Fig. 9; Fig. 17).

Regarding claims 10 and 11, Wittwer et al. teach detection of the fluorescent signal in real time and after each cycling step (col. 30, lines 30-60; col. 31, lines 22-28; Fig. 17).

Regarding claims 12-14, Wittwer et al. teach that the number of steps after which FRET signal is detectable depends on the template concentration (Fig. 17, for example). Therefore,  $10^4$  copies of the template can be detected after 25 cycles, whereas  $10^3$  copies are detected after 30 cycles, and 10 and 100 copies are detected after 40 cycles.

Regarding claims 26 and 27, Wittwer et al. teach discrimination of different templates by determining the melting temperature of the probes, to discriminate between homozygous and

Art Unit: 1637

heterozygous individuals with wild-type and mutant DNA (either a single probe or a pair of probes) (col. 43, lines 40-67; col. 44; col. 45, lines 1-47; Fig. 46; col. 46, lines 19-48; Fig. 48).

Regarding claim 28, Wittwer et al. teach different acceptor moieties, e.g. rhodamine, Cy5 or Cy 5.5 (col. 25, lines 62-67; col. 26, lines 8-13; col. 27, lines 20, 21).

Regarding claim 41, Wittwer et al. teach amplification employing a polymerase having a 3' to 5' exonuclease activity (Fig. 5B; col. 30, lines 30-60; col. 31, lines 5-20; Fig. 15).

Regarding claim 43, Wittwer et al. teach the acceptor moiety, rhodamine, being a quencher (col. 30, lines 33, 34).

Regarding claim 48, Wittwer et al. teach determination of the melting curves of three different amplification products using SYBRGreenI. The three fragments were amplified from hepatitis B surface antigen, PSA and beta-globin genes. The y could be distinguished on the basis of the differences in their melting temperatures (col. 37, lines 49-67; col. 38, lines 1-27; Fig. 37).

It would have been *prima facie* obvious to one of ordinary skill in the art to have used FRET-based amplification detection techniques of Wittwer et al. in the B. pertussis and B. parapertussis detection method of Van der Zee et al. The motivation to do so, provided by Wittwer et al., would have been that PCR was performed rapidly and the reaction monitored continuously, allowing adjustment of parameters (col. 4, lines 15-18), the total time required for PCR amplification and analysis was decreased (col. 4, lines 27-31) and desired from undesired products and different amplification products were distinguished on the basis of melting curves (col. 5, lines 1-15).

13. Claims 2 and 3 are rejected under 35 U.S.C. 103(a) as being unpatentable over Van der Zee et al. (J. Clin. Microbiol., vol. 31, pp. 2134-2140, 1993 ; cited in the IDS) and Wittwer et al. (U.S. Patent No. 6,174,670), as applied to claim 1 above, and further in view of Mc Lafferty et al. (J. Gen.

Art Unit: 1637

Microbiol., vol. 134, pp. 2297-2306, 1988) and Buck et al. (Biotechniques, vol. 27, pp. 528-536, 1999).

A) Regarding claims 2 and 3, Van der Zee et al. teach IS481-specific primers BP1 and BP4, hybridizing to bp 208-228 and 476-496 of IS481, and a probe cut out from the IS481 with ClaI and HpaI (page 2136, second and fourth paragraphs). Van der Zee et al. teach the primers based on a IS481 sequence of McLafferty et al. (page 2136, second paragraph).

B) Van der Zee et al. do not specifically teach primers with SEQ ID NO: 1 and 2 and probes with SEQ ID NO: 3 and 4.

C) As can be seen from sequence alignments, SEQ ID NO: 1 is complementary to bp 684-701 of the IS481 sequence of McLafferty et al., SEQ ID NO: 2 is complementary to bp 895-917 of the IS481 sequence of McLafferty et al., SEQ ID NO: 3 is complementary to bp 814-841 of the IS481 sequence of McLafferty et al., and SEQ ID NO: 4 is complementary to bp 843-870 of the IS481 sequence of McLafferty et al.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine the method of Van der Zee et al. and Wittwer et al. with the use of functionally equivalent primers selected from the sequence of McLafferty et al., since Van der Zee et al. expressly teach primer selection from the *B. pertussis* published sequence and since McLafferty et al. provide such published sequence.

In the recent court decision *In Re Deuel* 34 USPQ 2d 1210 (Fed. Cir. 1995), the Court of Appeals for the Federal Circuit determined that the existence of a general method of identifying a specific DNA does not make the specific DNA obvious. Regarding structural or functional homologs, however, the Court stated,

"Normally, a *prima facie* case of obviousness is based upon structural similarity, i.e., an established structural relationship between a prior art compound and the claimed compound. Structural

Art Unit: 1637

relationships may provide the requisite motivation or suggestion to modify known compounds to obtain new compounds. For example, a prior art compound may suggest its homologs because homologs often have similar properties and therefore chemists of ordinary skill would ordinarily contemplate making them to try to obtain compounds with improved properties (see page 9, paragraph 4 of attached ref)."

Since the claimed primers simply represent structural homologs, which are derived from sequences suggested by the prior art as useful for primers and probes for the detection of B. pertussis, and concerning which a biochemist of ordinary skill would attempt to obtain alternate compounds with improved properties, the claimed primers and probes are *prima facie* obvious over the cited references in the absence of secondary considerations.

Buck et al. expressly provides evidence of the equivalence of primers. Specifically, Buck et al. invited primer submissions from a number of labs (39) (page 532, column 3), with 69 different primers being submitted (see page 530, column 1). Buck et al. also tested 95 primers spaced at 3 nucleotide intervals along the entire sequence at issue, thereby testing more than 1/3 of all possible 18 mer primers on the 300 base pair sequence (see page 530, column 1). When Buck et al. tested each of the primers selected by the methods of the different labs, Buck et al. found that EVERY SINGLE PRIMER worked (see page 533, column 1). Only one primer ever failed, No. 8, and that primer functioned when repeated. Further, EVERY SINGLE CONTROL PRIMER functioned as well (see page 533, column 1). Buck et al. expressly states "The results of the empirical sequencing analysis were surprising in that nearly all of the primers yielded data of extremely high quality (page 535, column 2)." Therefore, Buck et al. provides direct evidence that all primers would be expected to function, and in particular, all primers selected according to the ordinary criteria, however different, used by 39 different laboratories. It is particularly striking that all 95 control primers functioned, which represent 1/3 of all possible primers in the target region. This clearly shows that every primer would have a reasonable expectation of success.

14. Claims 15-17 are rejected under 35 U.S.C. 103(a) as being unpatentable over Van der Zee et al. (J. Clin. Microbiol., vol. 31, pp. 2134-2140, 1993 ; cited in the IDS) and Wittwer et al. (U.S.

Art Unit: 1637

Patent No. 6,174,670), as applied to claim 1 above, and further in view of Longo et al. (Gene, vol. 93, pp. 125-128, 1990).

A) Neither Van der Zee et al. nor Wittwer et al. teach preventing amplification of contaminating nucleic acid by performing amplification in the presence of uracil and uracil-DNA glycosylase.

B) Regarding claims 15-17, Longo et al. teach PCR amplification reaction with uracil and uracil-DNA glycosylase (UDG) (page 126, second and third paragraph; page 127, paragraphs 2-4; Fig. 3).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the method of preventing contaminant amplification of Longo et al. in the combined detection method of Van der Zee et al. and Wittwer et al. The motivation to do so, provided by Longo et al., would have been that using UTP and UDG prevented occurrence of false positive results in PCR (Abstract).

15. Claim 21 is rejected under 35 U.S.C. 103(a) as being unpatentable over Van der Zee et al. (J. Clin. Microbiol., vol. 31, pp. 2134-2140, 1993 ; cited in the IDS) and Wittwer et al. (U.S. Patent No. 6,174,670), as applied to claim 1 above, and further in view of McMillan (U.S. Patent No. 6,312,929).

A) Regarding claim 21, Van der Zee et al. teach an internal control, but do not teach control probes and primers different from the IS481 probes or primers.

B) McMillan teaches internal controls for amplification reactions (Abstract), which can be used in reactions with FRET, molecular beacon and TaqMan probes (col. 13, lines 1-6, 32-48; col. 14, lines 34-54). The amplification reaction contains two internal control probes (HP2 and HP3)



Art Unit: 1637

and a pair of control primers (P3 and P4), designed for two internal controls, IC1 and IC2, different from the target sequence (Fig. 1; col. 2, lines 66 and 67; col. 3, lines 1-38; col. 6, lines 16-63).

It would have been *prima facie* obvious to one of ordinary skill in the art to have used a pair of control primers and a pair of control probes of McMillan in the detection method of Van der Zee et al. and Wittwer et al. The motivation to do so, provided by McMillan, would have been that using the internal controls allowed quantitation of the amplification reaction products in a single reaction and in real time (col. 16, lines 15-23).

16. Claims 23 and 24 are rejected under 35 U.S.C. 103(a) as being unpatentable over Van der Zee et al. (=Van der Zee1) (J. Clin. Microbiol., vol. 31, pp. 2134-2140, 1993 ; cited in the IDS) and Wittwer et al. (U.S. Patent No. 6,174,670), as applied to claim 22 above, and further in view of Van der Zee et al. (=Van der Zee2) (J. Bacteriol., vol. 175, pp. 141-147, 1993; cited in the IDS) and Buck et al. (Biotechniques, vol. 27, pp. 528-536, 1999).

A) Regarding claims 23 and 24, Van der Zee1 teach IS1001-specific primers BPPA and BPPZ, hybridizing to bp 1211-1232 and 734-755 of IS1001, and a probe cut out from the IS1001 with PstI (page 2136, second and fourth paragraphs). Van der Zee1 teach that the primers based on a IS1001 sequence of Van der Zee2 (page 2136, second paragraph).

B) Van der Zee1 do not specifically teach primers with SEQ ID NO: 5 and 6 and probes with SEQ ID NO: 7 and 8.

C) As can be seen from sequence alignments, SEQ ID NO: 5 is complementary to bp 375-392 of the IS1001 sequence of Van der Zee2, SEQ ID NO: 6 is complementary to bp 556-574 of the IS1001 sequence of Van der Zee2, SEQ ID NO: 7 is complementary to bp 457-480 of the IS1001 sequence of Van der Zee2, and SEQ ID NO: 8 is complementary to bp 482-503 of the IS1001 sequence of Van der Zee2 et al.

It would have been *prima facie* obvious to one of ordinary skill in the art at the time the invention was made to combine the method of Van der Zee1 and Wittwer et al. with the use of functionally equivalent primers selected from the sequence of Van der Zee1, since Van der Zee1 expressly teach primer selection from the B. parapertussis from published sequence and since Van der Zee2 provide such published sequence.

In the recent court decision *In Re Deuel* 34 USPQ 2d 1210 (Fed. Cir. 1995), the Court of Appeals for the Federal Circuit determined that the existence of a general method of identifying a specific DNA does not make the specific DNA obvious. Regarding structural or functional homologs, however, the Court stated,

"Normally, a *prima facie* case of obviousness is based upon structural similarity, i.e., an established structural relationship between a prior art compound and the claimed compound. Structural relationships may provide the requisite motivation or suggestion to modify known compounds to obtain new compounds. For example, a prior art compound may suggest its homologs because homologs often have similar properties and therefore chemists of ordinary skill would ordinarily contemplate making them to try to obtain compounds with improved properties (see page 9, paragraph 4 of attached ref)."

Since the claimed primers simply represent structural homologs, which are derived from sequences suggested by the prior art as useful for primers and probes for the detection of B. parapertussis, and concerning which a biochemist of ordinary skill would attempt to obtain alternate compounds with improved properties, the claimed primers and probes are *prima facie* obvious over the cited references in the absence of secondary considerations.

Buck et al. expressly provides evidence of the equivalence of primers. Specifically, Buck et al. invited primer submissions from a number of labs (39) (page 532, column 3), with 69 different primers being submitted (see page 530, column 1). Buck et al. also tested 95 primers spaced at 3 nucleotide intervals along the entire sequence at issue, thereby testing more than 1/3 of all possible 18 mer primers on the 300 base pair sequence (see page 530, column 1). When Buck et al. tested each of the primers selected by the methods of the different labs, Buck et al. found that EVERY SINGLE PRIMER worked (see page 533, column 1). Only one primer ever failed, No. 8, and that

primer functioned when repeated. Further, EVERY SINGLE CONTROL PRIMER functioned as well (see page 533, column 1). Buck et al. expressly states "The results of the empirical sequencing analysis were surprising in that nearly all of the primers yielded data of extremely high quality (page 535, column 2)." Therefore, Buck et al. provides direct evidence that all primers would be expected to function, and in particular, all primers selected according to the ordinary criteria, however different, used by 39 different laboratories. It is particularly striking that all 95 control primers functioned, which represent 1/3 of all possible primers in the target region. This clearly shows that every primer would have a reasonable expectation of success.

17. Claims 44 and 45 are rejected under 35 U.S.C. 103(a) as being unpatentable over Van der Zee et al. (J. Clin. Microbiol., vol. 31, pp. 2134-2140, 1993 ; cited in the IDS) and Wittwer et al. (U.S. Patent No. 6,174,670), as applied to claim 40 above, and further in view Tyagi et al. (U.S. patent No. 5,925,517).

A) Regarding claim 45, Wittwer et al. teach the acceptor moiety, rhodamine, being a quencher (col. 30, lines 33, 34). Wittwer et al. do not teach probes forming a secondary structure which brings the donor and acceptor into spatial proximity.

B) Regarding claim 44, Tyagi et al. teach probes which contain a part complementary to a target and two parts on either side of the complement which can form a secondary structure when not hybridized to the target. The probes contain labels on either end of the probe. When the probe is not bound to the target, the labels are in close proximity, whereas in the presence of a target they become separated, changing the signal from the labels, which are FRET labels (Fig. 3; col. 4, lines 59-67; col. 5, lines 1-67; col. 6, lines 1-7; col. 16, lines 13-22, 41-59).

It would have been *prima facie* obvious to one of ordinary skill in the art at the time of the invention to have used the probes of Tyagi et al. in the detection method of Van der Zee et al. and

Art Unit: 1637

Wittwer et al. The motivation to do so, provided by Tyagi et al., would have been that unimolecular probes generated signal upon hybridization to nucleic acids, but no signal in the absence of hybridization (col. 3, lines 55-58), were used in real-time detection (col. 4, lines 5-8), did not require expensive equipment (col. 4, lines 9-11) and distinguished between closely related nucleic acids (col. 4, lines 12-16).

18. No claims are allowed.


***Conclusion***

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Teresa E Strzelecka whose telephone number is (571) 272-0789. The examiner can normally be reached on M-F (8:30-5:30).

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Gary Benzion can be reached on (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 703-872-9306.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free).

TS  
February 19, 2004

  
JEFFREY FREDMAN  
PRIMARY EXAMINER